Movalis (Meloxicam)

Meloxicam, the active ingredient in Movalis, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for oral use. It is prescribed to relieve pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute musculoskeletal pain in adult patients.

GNH USA supplies Movalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Movalis (meloxicam) is used within the musculoskeletal and inflammatory disease spectrum to reduce pain and swelling. - Osteoarthritis: improves joint function and reduces chronic pain. - Rheumatoid arthritis: diminishes synovial inflammation and joint damage progression. - Ankylosing spondylitis: alleviates spinal stiffness and inflammatory pain. - Acute pain: provides short‑term relief of moderate to severe pain after injury or surgery.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Peripheral edema: mild swelling of the lower limbs.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding, potentially life‑threatening. - Cardiovascular events such as myocardial infarction or stroke. - Severe skin reactions, including Stevens‑Johnson syndrome. - Hepatic injury: elevated liver enzymes or hepatitis.

Before initiating therapy, clinicians should consider several safety measures. - Renal function assessment: adjust use in patients with impaired kidney function. - Gastrointestinal risk evaluation: avoid in individuals with a history of ulcer disease. - Cardiovascular monitoring: use cautiously in patients with established heart disease. - Hypersensitivity screening: discontinue if allergic reactions occur. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Meloxicam may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: heightened gastrointestinal toxicity. - Lithium: elevated lithium serum concentrations. - Methotrexate: possible enhanced toxicity.

Moderate Interactions (Monitor Closely):\n- Diuretics: may reduce renal clearance of meloxicam. - ACE inhibitors or ARBs: potential for reduced renal function. - Selective serotonin reuptake inhibitors (SSRIs): modest increase in bleeding risk. - Corticosteroids: additive gastrointestinal irritation.